A total of 1200 patients had undergone I-125 prostate brachytherapy (BXT) in our centre. We present prospective outcome data for the first 400 treated patients. Data were analysed from a prospective database of 400 consecutive patients treated with permanent prostate BXT between March 1999 and December 2003. Patients were stratified into low (49%), intermediate (36%) and high (15%) risk as defined by the Memorial Sloan-Kettering Prognostic Index. Patients received 145 Gy BXT alone (41%), BXT with 3 months neoadjuvant androgen deprivation (NAAD) (39%), 45 Gy external beam radiotherapy (EBRT) with 110 Gy BXT (3%) or a combination of NAAD, 45 Gy EBRT and 110 Gy BXT (17%). Biochemical relapse-free survival (bRFS) and prostate-specific antigen (PSA) nadirs were analysed for treatment received in each risk group. Median follow-up was 54 months (range, 38-96 months) with a mean patient age of 63 years. Prostate cancer-specific survival was 99.5%. Twentyeight patients (7%) experienced biochemical failure according to the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology (RTOG-ASTRO) Phoenix Consensus definition (PSA nadir plus X2 ng ml À1 ): nine low-, fourteen intermediate-and five high-risk patients. When stratified by treatment group for low-, intermediate-and high-risk groups, the 5-year actuarial bRFS was 98, 89 and 100% for BXT; 91, 87 and 88% for NAAD and BXT; 100, 80 and 100% for EBRT and BXT; and 100, 92 and 88% for NAAD, EBRT and BXT, respectively. Overall 4-and 5-year PSA p0.5 ng ml À1 was achieved by 83 and 86%. This prospective study updates our biochemical survival results, and further demonstrates that the UK centres are able to reproduce the excellent US-reported outcomes for BXT.
Introduction
With treatment options for localized prostate cancer increasing both in number and complexity, it is important to continually re-appraise each modality in order to impart a balanced view when discussing therapeutic options. Interstitial low-dose rate (LDR) prostate brachytherapy (BXT) remains a first-line treatment option, and advances in technology, implant technique, patient selection, and understanding of the tolerances of critical structures, continue to improve the therapeutic ratio of this procedure. [1] [2] [3] [4] Despite the lack of randomized controlled trials, the biochemical relapse-free (bRFS) survival data for prostate BXT in organ-confined disease has been shown to be comparable to that of radical prostatectomy and external beam radiotherapy (EBRT). [5] [6] [7] [8] [9] [10] [11] [12] Furthermore, experience from the United Kingdom has been reported to match the standard set by the US centres. 13 A recent retrospective study of over 60 000 men with organ-confined low and moderate grade prostate cancer from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program showed that a better survival was observed in men treated with surgery or BXT, as compared to no definitive therapy. The magnitude of the benefit on prostate cancer-specific mortality and any-cause mortality was similar for both definitive therapies irrespective of age. 14 The UK National Institute for Clinical Excellence has recommended that centres performing LDR BXT continue further research and audit to address clinical outcomes and long-term survival. 15 In Guildford, the LDR iodine (I)-125 prostate BXT program was implemented in March 1999, and to date 1100 patients have been treated. This study updates our previously reported results, using prospectively collected data from the first 400 treated patients at our centre. 13, 16 In order that our results are consistent with current literature, we have used the most recent 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology (RTOG-ASTRO) Phoenix Consensus definition of biochemical failure (prostatespecific antigen (PSA) nadir plus X2 ng ml
À1
) to determine clinical outcome of these patients.
Methods
Between Deviation from this treatment protocol occurred in less than 5% of cases, and such patients were treated as a result of individual factors including presence of perineural invasion, young age (o60 years) and delay in treatment decision or funding application. The length of NAAD was 4-12 months, and no patients received adjuvant androgen deprivation therapy.
A two-stage implant technique was used. 3 The prostate volume and pubic arch were assessed using TRUS with the patient in the extended lithotomy position. A series of transverse images were acquired from base to apex at 5 mm intervals. These images were digitized into the planning computer, and the seed distribution generated. The implant took place up to 4 weeks later, using needles pre-loaded with stranded seeds (RapidStrand, Oncura, Plymouth Meeting, PA, USA) inserted transperineally. Computed tomography (CT)-based dosimetry was obtained at Day 30 postimplant.
Patients were followed-up 3-6 monthly from the date of implant for 5 years, and annually thereafter. A bespoke prospective database was used to record PSA response and clinical data. The IPSS and IIEF-5 questionnaires were used at each follow-up interval to assess toxicity. The IIEF-5 is a validated, sensitive and specific tool, which is widely recognized for the assessment of erectile function post-BXT. 18, 19 As part of our treatment protocol, phosphodiesterase-5 (PDE-5) inhibitor use was routinely encouraged, particularly in the first year postimplant, to maintain optimal erectile function. 20, 21 Biochemical failure was defined by a rise in PSA above the absolute nadir of X2 ng ml
À1
. This corresponds with the 2006 RTOG-ASTRO Phoenix Consensus definition, with the point of failure being taken 'at the call' and not backdated. 22 For patients with localized prostate cancer treated by permanent isotopic implant and EBRT, this definition is reported to provide the best surrogate for failure. 23 Patients whose PSA subsequently fell were classified as experiencing a PSA 'bounce' rather than biochemical failure. Clinical failure was defined as radiologically confirmed distant relapse or biopsyproven local recurrence.
Survival analysis methods were used to derive the time to biochemical failure. The Kaplan-Meier product limit method was used to construct survival curves where survival was considered as the duration that a patient was PSA relapse free. Each patient is represented as a failure, censored observation or PSA relapse free at the latest follow-up. PSA nadirs were examined as a surrogate end point for bRFS. Biochemical relapse-free survival JP Nobes et al high risk. The mean age of all patients was 68 years. The patients' characteristics and treatment received are summarized in Tables 1 and 2 . PSA bounce occurred in 113 (28.3%) of men during follow-up. There were two deaths from prostate cancer, and nine from other causes (four cardiovascular deaths, one from carcinoma of the sigmoid colon, two from carcinoma of the lung, one from a primary brain tumour and one from unknown causes). One patient with intermediate-risk disease (T2b, PSA 9.4 ng ml À1 , Gleason sum 8) received NAAD, EBRT and BXT, failed at 27 months with bone metastases, and died at 37 months from complications of spinal cord compression. The other patient had high-risk disease after histological review (T2c, PSA 6 ng ml À1 , Gleason sum 5, upgraded to 7) was treated with BXT alone, developed bone metastases at 15 months and died from meningeal disease at 26 months.
The 5-year actuarial bRFS was 95% for the low-risk, 88% for the intermediate-risk and 90% for the high-risk groups; for all patients it was 92% (Figure 1) . When stratified by treatment received, low-risk patients had a 5-year actuarial bRFS of 98% for BXT alone (n ¼ 120), 91% for NAAD and BXT (n ¼ (Table 3) .
A number of men received individualized treatments due to tumour and patients factors. This has resulted in some treatment groups containing small numbers, and it must be noted that Kaplan-Meier estimates of bRFS are unlikely to be valid for groups of less than 10 patients.
In total, 28 patients experienced biochemical failure as defined by the 2006 RTOG-ASTRO criteria (PSA nadir plusX2 ng ml À1 ); of these, 11 had clinically relapsed. The characteristics of these patients and salvage treatments received are shown in Table 4 . Considering the primary treatment modality, 6 were treated by BXT alone, 15 with NAAD and BXT, 1 with EBRT and BXT and 6 with NAAD, EBRT and BXT. Of the 28 patients in whom treatment failed, 21 had received NAAD. Of these, four reached a PSA nadir of p0.2 ng ml
. Two of the seven who did not receive NAAD reached a nadir PSA of p0.5.
In terms of salvage therapy, two patients had a radical prostatectomy, one retropubically and the other laparoscopically. The first has an undetectable PSA at 5 years after surgery, the latter subsequently failed biochemically. Table 5 summarizes the PSA nadirs at 4 and 5 years following treatment. Values are shown for all patients, and stratified by prognostic group and by whether NAAD was given. For all patients, at 4 years after treatment, 83% of values were p0.5 ng ml À1 (n ¼ 189) and 57% were p0.2 (n ¼ 130). At 5 years post-implant, 86% of values were p0.5 ng ml À1 (n ¼ 110) and 77% were p0.2 (n ¼ 98). There was no significant difference in the proportion of men with PSA p0.5 at 4 years treated with or without androgen deprivation.
Day 30 CT post-implant dosimetry was recorded in 352 patients. Mean D 90 was 145.7 Gy (±21.1) in those treated with monotherapeutic BXT, and 110.4 Gy ( ± 16.6) in patients who received BXT as a boost after EBRT.
Of the 400 patients treated, 60 (15%) experienced acute urinary retention (AUR); 39 of these had received NAAD therapy, although whether this was for cytoreductive or 92% 5-year PSA relapse-free survival Figure 1 Prostate-specific antigen (PSA) relapse-free survival for the first 400 patients treated at our centre. 
Abbreviations: BXT, brachytherapy; EBRT, external beam radiotherapy; NAAD, neoadjuvant androgen deprivation.
Biochemical relapse-free survival JP Nobes et al disease-related purposes is not currently documented in our database. In total, 10 patients (2.5%) required a TURP for bothersome lower urinary tract symptoms; none of these patients had subsequent continence problems. In all, 32 patients (8%) developed membranous urethral strictures requiring dilatation, and one had temporary urinary leakage after the procedure. Five of these stricture patients had received BXT as a boost after EBRT. The median time to stricture was 30 months (range, 10-54 months), and there were no bladder neck stenoses recorded. Ten patients who received treatment for stricture carry out long-term intermittent self-catheterization (ISC). In total, 226 patients (57%) were potent at baseline as determined by an IIEF-5 score of X11. At 2 years, 64% of these remained potent, with 60% of potent patients using a PDE-5 inhibitor. Radiation proctitis of any severity occurred in 26 (6.5%) of patients, with 11 (2.75%) of these reporting post-implant rectal bleeding.
Discussion
Primary radical therapeutic options for organ-confined prostate cancer include radical prostatectomy, EBRT and interstitial BXT. At present, none of these modalities has been shown to be superior. Retrospective analyses of early-stage disease treated with surgery or radiation have found no difference in rates of bRFS. 9, 11, 12 This prospective study of 400 patients has shown the excellent bRFS rates achieved with interstitial LDR prostate BXT in men with clinical stage T1-T3a prostate cancer. Direct comparison with published data from the US is difficult due to differences in selection criteria, treatment combinations and length of follow-up.
We acknowledge that a significant number of men received NAAD (56%). With a short follow-up period, this will influence PSA relapse-free survival. However, the 5-year actuarial bRFS of 92%, with 95% for low-risk, 88% for intermediate-risk and 90% for high-risk patients, is encouraging and consistent with published reports. 5, 6, 13, 24 The results for the high-risk group are better than one might expect. This may be explained by the fact that there were few high-risk patients; or that the combination treatment of NAAD, EBRT and BXT might have been effective in preventing recurrence. Receiving combination treatment may also have delayed the time to recurrence, which will become evident as the data matures. The Memorial Sloan-Kettering prognostic stratification was used, which defines high-risk patients as having at least two risk factors from a PSA level of 410 ng ml
À1
, a Gleason sum of 46 and stage 4T2b. Thus, some patients defined here a high risk might be considered to have relatively favourable disease when compared to other series.
Given the relatively short follow-up period, PSA nadirs were also assessed. These have been demonstrated to be predictive for biochemical freedom from disease after EBRT and BXT; nadirs of p0.5 ng ml À1 being associated with a 5-year bRFS of 93%. 25 Although NAAD will affect PSA levels for the first year after treatment, at 4 years 83% (189) and at 5 years 86% (110) of patients had a PSA p0.5. There was no difference between those treated with or without NAAD (as shown in Table 5 ), which supports the durability of these results.
PSA bounce has been reported to occur in up to 40% of men treated with prostate BXT with a follow-up of 430 months. 26 In our series, with a median follow-up of 54 months, the PSA bounce rate was 28%; and this might have been influenced by the use of androgen suppression in some patients.
The most significant acute toxicities after prostate BXT are AUR and irritative and obstructive LUTS. In total, 15% of patients in the analysis experienced AUR, which is consistent with the published rates of 5-15%. [27] [28] [29] Preimplant IPSS, baseline prostate volume and urodynamic status influenced whether ISC was used. 30 Of the 400 patients analysed, 8% developed urethral strictures which responded well to dilatation followed by weekly ISC to prevent recurrence. The risk of urethral stricture after prostate cancer treatment has been reported to be between 1.1 and 8.4% depending on treatment type. The risk was highest after radical prostatectomy or BXT plus EBRT. 31 A potent IIEF-5 score of X11 was reported by 64% of respondents after BXT. In total, 60% of these patients used a PDE-5 inhibitor to optimize their erectile function, although the more precise details of dosage and administration were not recorded in our database. PDE5-inhibitor use is actively encouraged as part of the routine treatment protocol, particularly in the first postimplant year. 20, 21 The IIEF-score is a patient-completed questionnaire, which is only valid in those men who have been sexually active in the preceding month and does not take into account the potential for intercourse. This is a limitation of the design and may lead to an overestimation of erectile dysfunction rates by counting abstinent patients as impotent. The influence of factors such as delayed treatment waiting times meant that, in this cohort, NAAD was used on a relatively frequent basis, and often for longer than the standard 3 months prior to radiotherapy. This is relevant when reporting toxicity, as prolonged use of NAAD will have a negative impact on the subsequent prevalence erectile dysfunction. This centre has recently reported an 86.6% potency preservation rate at 1 year in men treated with BXT alone, with the use of a penile bulb-sparing modified implant technique (47% PDE-5 inhibitor use). 32 Of the 11 patients, who died in this series, one patient died of colorectal adenocarcinoma. The rate of second malignancies following localized therapy for prostate cancer has been recently studied: an increased but small risk of developing a second malignancy after BXT has been reported, although it was acknowledged that this may be due to more vigilant screening as a result of radiation side-effects, genetic and environmental predisposing conditions. 33 However, a review of the SEER registry showed for the first time that patients who received BXT had the lowest odds of developing second cancers, despite the higher radiation doses delivered when compared to EBRT. 34 Another recent review reported an increased risk of second cancers after external radiation, but not after BXT. 35 It is too early to comment on the rate of second malignancies in this cohort as yet, but future studies will be able to focus on this issue when the follow-up duration matures.
In conclusion, this prospective series updates our previous results and confirms the excellent overall biochemical survival rate after I-125 prostate BXT. The treatment is well tolerated, with urinary toxicity and erectile dysfunction rates consistent with published data.
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